Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast

Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment algorithms for nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Some patients with mCRPC are receiving triple combinations of current therapies. The dynamic late-phase pipeline mostly focuses on mCRPC and comprises a plethora of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna, Roche’s ipatasertib, AstraZeneca’s capivasertib) and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s 177Lu-PSMA-617, Telix’s 77Lu-DOTA-rosopatamab, POINT Biopharma’s 177Lu-PNT2002). These agents will likely contribute to robust market growth over the 2021-2031 forecast period.

QUESTIONS ANSWERED

  • What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?
  • What are the key drivers and constraints in the prostate cancer therapy market, and how will the major markets evolve over the 10-year forecast period?
  • What is the current state of treatment for prostate cancer? What are interviewed experts’ insights on these treatment options?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will their positioning and uptake in the market be?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • Prostate Cancer Key Findings
    • Key updates
      • January 2023
      • Q4 2022
        • December 2022
        • October 2022
      • Q3 2022
        • September 2022
        • August 2022
      • Q2 2022
        • May 2022
        • April 2022
    • Market outlook
      • Key findings
        • Major-market share of prostate cancer drug classes: 2021
        • Major-market sales of prostate cancer drug classes: 2031
        • Drug-treatable population share and major-market sales share: 2021
        • Drug-treatable population share and major-market sales share: 2031
        • Population positioning of therapies in prostate cancer
        • Prostate cancer SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for prostate cancer?
        • What factors are constraining the market for prostate cancer?
        • Major-market sales of key agents for prostate cancer: 2021-2031
        • Major-market sales for prostate cancer by region: 2021, 2026, and 2031
        • Major-market sales for prostate cancer by drug class: 2021-2031
      • Segment-specific trends
        • Major-market share of key agents for metastatic hormone-sensitive prostate cancer: 2031
        • Patient-share dynamics of key agents for newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer in the United States: 2021-2031
        • Patient-share dynamics of key agents for biochemically recurrent hormone-sensitive prostate cancer in the United States: 2021-2031
        • Patient-share dynamics of key agents for metastatic hormone-sensitive prostate cancer in the United States: 2021-2031
        • Patient-share dynamics of key hormonal agents for nonmetastatic castrate-resistant prostate cancer in the United States: 2021-2031
        • Patient-share dynamics of key therapies in first-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
        • Patient-share dynamics of key therapies in first-line metastatic castrate-resistant prostate cancer in France: 2021-2031
        • Share of major-market sales in first-line metastatic castrate-resistant prostate cancer by agent: 2031
        • Patient-share dynamics of key therapies in second-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
        • Patient-share dynamics of key therapies in second-line metastatic castrate-resistant prostate cancer in France: 2021-2031
        • Patient-share dynamics of key therapies in third- and fourth-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
        • Patient-share dynamics of key therapies in third- and fourth-line metastatic castrate-resistant prostate cancer in France: 2021-2031
        • Share of major-market sales in second- and subsequent-line metastatic castrate-resistant prostate cancer by drug class: 2031
    • Forecast
      • Market forecast assumptions
      • Market forecast dashboard
    • Etiology and pathophysiology
      • Key findings
        • Disease overview
      • Disease pathophysiology
        • Biology and metastatic spread of prostate cancer
        • Development of castrate-resistant prostate cancer
        • Molecular alterations involved in castrate-resistant prostate cancer
        • Prostate-specific antigen
        • Key clinical uses of prostate-specific antigen as a biomarker in prostate cancer
        • Staging classification and grading systems for prostate cancer
        • TNM staging classification system for prostate cancer
        • Classification of level of risk of recurrence of prostate cancer
      • Key pathways and drug targets
        • Androgen receptor-signaling pathway
        • Androgen-mediated growth of normal and cancerous prostate cells
        • Splice variants of the androgen receptor
        • Emerging drug targets in prostate cancer
        • PARP inhibition: mechanism of action
        • Immune checkpoint inhibitors and modulators
      • Anatomic location and architecture of the prostate gland
    • Epidemiology
      • Key findings
        • Key updates
      • Epidemiology populations
        • Disease definition
        • Methods
        • Sources used for diagnosed incidence of prostate cancer
        • Number of diagnosed incident cases of prostate cancer in the major pharmaceutical markets: 2021-2031
        • Disease definition
        • Methods
        • Sources used for TNM stage and NCCN risk categories of prostate cancer
        • Diagnosed incident cases of prostate cancer in the major pharmaceutical markets by TNM stage and NCCN risk category: 2021-2031
        • Disease definition
        • Methods
        • Sources used for recurrent incidence of prostate cancer
        • Number of biochemically and metastatic recurrent incident cases of prostate cancer in the major pharmaceutical markets: 2021-2031
        • Sources used for drug-treatable prostate cancer population
        • Drug-treatable cases of prostate cancer in the major pharmaceutical markets: 2021-2031
        • Prostate cancer patient-flow model
        • Sources used for prostate cancer drug-treated population
        • Drug-treated cases of prostate cancer in the major pharmaceutical markets: 2021-2031
    • Current treatment
      • Key findings
        • Treatment goals
          • Key endpoints used in clinical trials for prostate cancer
        • Key current therapies
          • Overview
          • Mechanism of action of key current drug classes used for prostate cancer
          • Current treatments used for prostate cancer
          • Market events impacting the use of key current therapies for prostate cancer
          • Advantages and disadvantages of Zytiga
          • Key results from clinical trials investigating Zytiga for the treatment of prostate cancer
          • Ongoing clinical development of Zytiga
          • Key ongoing clinical trials of Zytiga in the treatment of prostate cancer
          • Expert insight: Zytiga
          • Advantages and disadvantages of Xtandi
          • Key results from clinical trials investigating Xtandi for the treatment of prostate cancer
          • Ongoing clinical development of Xtandi
          • Key ongoing clinical trials of Xtandi in the treatment of prostate cancer
          • Expert insight: Xtandi
          • Key results from select clinical trials investigating Erleada for the treatment of prostate cancer
          • Ongoing clinical development of Erleada
          • Expert insight: Erleada
          • Key results from select clinical trials investigating Nubeqa for the treatment of prostate cancer
          • Ongoing clinical development of Nubeqa
          • Key ongoing clinical trials of Nubeqa in the treatment of prostate cancer
          • Expert insight: Nubeqa
          • Key results from select clinical trials investigating Yonsa for the treatment of prostate cancer
          • Expert insight: Yonsa
          • Advantages and disadvantages of LHRH agonists / antagonists
          • Expert insight: LHRH agonists / antagonists
          • Key results from select clinical trials investigating Orgovyx for the treatment of prostate cancer
          • Ongoing clinical development of Orgovyx
          • Expert insight: Orgovyx
          • Key results from select clinical trials investigating Pluvicto for the treatment of prostate cancer
          • Ongoing clinical development of Pluvicto
          • Key ongoing clinical trials of Pluvicto in the treatment of prostate cancer
          • Expert insight: Pluvicto
          • Advantages and disadvantages of Provenge
          • Key results from clinical trials investigating Provenge for the treatment of prostate cancer
          • Ongoing clinical development of Provenge
          • Key ongoing clinical trials investigating Provenge in the treatment of prostate cancer
          • Expert insight: Provenge
          • Advantages and disadvantages of Xofigo
          • Key results from clinical trials investigating Xofigo for the treatment of prostate cancer
          • Ongoing clinical development of Xofigo
          • Key ongoing clinical trials of Xofigo in the treatment of prostate cancer
          • Expert insight: Xofigo
          • Advantages and disadvantages of Jevtana
          • Key results from clinical trials investigating Jevtana for the treatment of prostate cancer
          • Ongoing clinical development of Jevtana
          • Expert insight: Jevtana
          • Advantages and disadvantages of docetaxel
          • Key results from clinical trials investigating docetaxel for the treatment of prostate cancer
          • Expert insight: docetaxel
          • Key results from select clinical trials investigating Lynparza for the treatment of prostate cancer
          • Ongoing clinical development of Lynparza
          • Key ongoing clinical trials of Lynparza in the treatment of prostate cancer
          • Expert insight: Lynparza
          • Key results from clinical trials investigating Rubraca for the treatment of prostate cancer
          • Ongoing clinical development of Rubraca
          • Key ongoing clinical trials of Rubraca in the treatment of prostate cancer
          • Expert insight: Rubraca
        • Medical practice
          • Newly diagnosed low- and intermediate-risk hormone-sensitive prostate cancer
          • Newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer
          • Metastatic hormone-sensitive prostate cancer
          • Biochemically recurrent prostate cancer
          • Nonmetastatic castrate-resistant prostate cancer
          • First-line metastatic castrate-resistant prostate cancer
          • Second- and subsequent-line metastatic castrate-resistant prostate cancer
          • Patient characteristics influencing drug selection in prostate cancer
          • Treatment decision tree for low- and intermediate-risk prostate cancer: major markets
          • Treatment decision tree for high-risk and N1M0 prostate cancer: major markets
          • Treatment decision tree for nonmetastatic castrate-resistant prostate cancer: United States
          • Treatment decision tree for metastatic hormone-sensitive prostate cancer: United States
          • Treatment decision tree for metastatic castrate-resistant prostate cancer: major markets
      • Unmet need overview
        • Current and future attainment of unmet needs in prostate cancer
        • Top unmet needs in prostate cancer: current and future attainment
        • Expert insight: unmet need in prostate cancer
      • Drug pipeline
        • Pipeline
        • Regulatory Milestones
        • Indication Comparison
      • Emerging therapies
        • Key findings
          • Key emerging therapies
            • Key therapies in development for prostate cancer
            • Estimated market authorization dates of key emerging therapies for the treatment of prostate cancer
            • Key results from select clinical trials investigating CAN-2409 for the treatment of prostate cancer
            • Analysis of clinical development program for CAN-2409
            • Key ongoing clinical trials of CAN-2409 in the treatment of prostate cancer
            • Expert insight: CAN-2409
            • Expectations for market authorization and sales opportunity of CAN-2409 in prostate cancer
            • Key results from clinical trials investigating Keytruda for the treatment of prostate cancer
            • Analysis of clinical development program for Keytruda
            • Key ongoing clinical trials of Keytruda in the treatment of prostate cancer
            • Expert insight: Keytruda
            • Expectations for market authorization and sales opportunity of Keytruda in prostate cancer
            • Key results from clinical trials investigating Opdivo for the treatment of prostate cancer
            • Analysis of clinical development program for Opdivo
            • Key ongoing clinical trials of Opdivo in the treatment of prostate cancer
            • Expert insight: Opdivo
            • Expectations for market authorization and sales opportunity of Opdivo in prostate cancer
            • Key results from clinical trials investigating Talzenna for the treatment of prostate cancer
            • Analysis of clinical development program for Talzenna
            • Key ongoing clinical trials of Talzenna in the treatment of prostate cancer
            • Expert insight: Talzenna
            • Expectations for market authorization and sales opportunity of Talzenna in prostate cancer
            • Key results from clinical trials investigating Zejula for the treatment of prostate cancer
            • Analysis of clinical development program for Zejula
            • Key ongoing clinical trials of Zejula in the treatment of prostate cancer
            • Expert insight: Zejula
            • Expectations for launch and sales opportunity of Zejula in prostate cancer
            • Key results from select clinical trials investigating ipatasertib for the treatment of prostate cancer
            • Analysis of clinical development program for ipatasertib
            • Expert insight: ipatasertib
            • Expectations for market authorization and sales opportunity of ipatasertib in prostate cancer
            • Key results from select clinical trials investigating capivasertib for the treatment of prostate cancer
            • Analysis of clinical development program for capivasertib
            • Key ongoing clinical trials of capivasertib in the treatment of prostate cancer
            • Expert insight: capivasertib
            • Expectation for market authorization and sales opportunity of capivasertib in prostate cancer
            • Key results from select clinical trials investigating 177Lu-DOTA-rosopatamab for the treatment of prostate cancer
            • Analysis of the clinical development program for 177Lu-DOTA-rosopatamab
            • Key ongoing clinical trials of 177Lu-DOTA-rosopatamab in the treatment of prostate cancer
            • Expert insight: 177Lu-DOTA-rosopatamab
            • Expectations for market authorization and sales opportunity of 177Lu-DOTA-rosopatamab in prostate cancer
            • Key results from select clinical trials investigating 177Lu-PNT2002 for the treatment of prostate cancer
            • Analysis of the clinical development program for 177Lu-PNT2002
            • Key ongoing clinical trials of 177Lu-PNT2002 in the treatment of prostate cancer
            • Expert insight: 177Lu-PNT2002
            • Expectations for market authorization and sales opportunity of 177Lu-PNT2002 in prostate cancer
            • Analysis of the clinical development program for 177Lu-PSMA-I&T
            • Key ongoing clinical trials of 177Lu-PSMA-I&T in the treatment of prostate cancer
            • Expert insight: 177Lu-PSMA-I&T
            • Expectations for market authorization and sales opportunity of 177Lu-PSMA-I&T in prostate cancer
            • Key results from select clinical trials investigating sabizabulin (VERU-111) for the treatment of prostate cancer
            • Analysis of the clinical development program for sabizabulin (VERU-111)
            • Key ongoing clinical trials of sabizabulin (VERU-111) in the treatment of prostate cancer
            • Expert insight: sabizabulin (VERU-111)
            • Expectations for market authorization and sales opportunity of sabizabulin (VERU-111) in prostate cancer
            • Key results from select clinical trials investigating Cabometyx for the treatment of prostate cancer
            • Analysis of clinical development program for Cabometyx
            • Key ongoing clinical trials of Cabometyx in the treatment of prostate cancer
            • Expert insight: Cabometyx
            • Expectations for market authorization and sales opportunity of Cabometyx in prostate cancer
            • Analysis of the clinical development program for Verzenio / Verzenios
            • Key ongoing clinical trials of Verzenio / Verzenios in the treatment of prostate cancer
            • Expert insight: Verzenio / Verzenios
            • Expectations for market authorization and sales opportunity of Verzenio / Verzenios in prostate cancer
            • Key results from clinical trials investigating vobramitamab duocarmazine for the treatment of prostate cancer
            • Analysis of the clinical development program for vobramitamab duocarmazine
            • Key ongoing clinical trials of vobramitamab duocarmazine in the treatment of prostate cancer
            • Expectations for market authorization and sales opportunity of vobramitamab duocarmazine in prostate cancer
          • Early-phase pipeline analysis
            • Select compounds in early-phase development for prostate cancer
        • Access and reimbursement overview
          • Region-specific reimbursement practices
            • Key market access considerations in prostate cancer: United States
            • General reimbursement environment: United States
            • Key market access considerations in prostate cancer: EU5
            • General reimbursement environment: EU5
            • Key market access considerations in prostate cancer: Japan
            • General reimbursement environment: Japan
        • Appendix
          • Abbreviations
          • Brands, Marketers, and Generic Availability of Current Therapies Used for Prostate Cancer by Market
          • Prostate cancer bibliography

      Login to access report